Advertisement
Advertisement

ADMA

ADMA logo

ADMA Biologics, Inc.

18.39
USD
+0.38
+2.14%
Apr 07, 15:59 UTC -4
Closed
exchange

After-Market

18.48

+0.08
+0.43%

ADMA Biologics, Inc. Profile

About

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Info & Links

CEO

Adam S. Grossman

Headquarters

465 STATE ROUTE 17
RAMSEY, NJ 07446, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.admabiologics.com

Auditor

CohnReznick LLP

Share holders

5

Employees

624

ADMA Biologics, Inc. Statistics

Valuation Measures

Market Capitalization2

4.39B

Enterprise Value

4.41B

Enterprise Value/EBITDA(ttm)

35.49

Price to Earnings Ratio(ttm)

40.20

Price to Sales(ttm)

9.93

Price to Book(mrq)

16.39

Price to Cash(ytd)

316.42

Profitability

Gross Margin(ttm)

51.26%

Operating Margin(ttm)

24.64%

Profit Margin(ttm)

44.20%

Return on Equity(ttm)

53.20%

Return on Invested Capital(ttm)

52.34%

Return on Assets(ttm)

26.07%

Income Statement

Revenue(ttm)

382.81M

Revenue Per Share(ttm)

1.62

Gross Profit(ttm)

187.31M

EBITDA(ttm)3

124.39M

Net Income Available to Common(ttm)

68.13M

Diluted EPS(ttm)

0.28

Share Statistics

Beta (5Y Monthly)

0.75

52-Week Change

187.87%

S&P 500 52-Week Change

-2.69%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

236.39M

Dividend Yield

0.00%

Float4

227.64M

% Held by Insiders

3.70%

% Held by Institutions

75.68%

Balance Sheet

Total Cash(mrq)

86.71M

Total Cash Per Share(mrq)

0.37

Total Debt(mrq)

111.38M

Total Debt/Equity(mrq)

23.53%

Current Ratio(mrq)

5.97%

Quick Ratio(mrq)

3.26%

Book Value Per Share(mrq)

1.48

Cash Flow

Operating Cash Flow Per Share(ytd)

0.49

Free Cash Flow(ytd)

110.45M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement